UK pharma leaders warn industry levy is driving investment away
Pharmaceutical leaders are warning that the UK is becoming an unattractive destination for investment due to high and unpredictable levies on medicine sales.
The industry is calling on the government to reform the Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (VPAG) to restore the country's global competitiveness The VPAG requires companies to return a significant portion of their revenues from branded medicines to the National Health Service (NHS), with rates rising sharply in 2025.
The Association of the British Pharmaceutical Industry (ABPI) has urged ministers to collaborate with the sector, arguing that the current system is undermining the government’s goal of making life sciences a pillar of the UK’s industrial strategy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze